Key result
The CHEMO-RADIAT score predicted major adverse cardiovascular events in breast cancer survivors with time-dependent C-indices of 0.876 at 3 years and 0.842 at 7 years in the validation cohort.
Why the study?
Cardiovascular disease is an important cause of mortality among survivors of breast cancer.
Does the CHEMO-RADIAT score accurately predict major adverse cardiovascular events in female patients with breast cancer?
Cohort (n=1,256)
1:1 for derivation and validation cohorts
Yes
Does the CHEMO-RADIAT score accurately predict major adverse cardiovascular events in female patients with breast cancer?
Effect estimate: C-index 0.876 at 3 years and 0.842 at 7 years
The CHEMO-RADIAT score provides a validated tool for predicting major adverse cardiovascular events in breast cancer survivors, aiding in multidisciplinary cardio-oncology care.
No takes yet. Share an insight, caveat, or question.
May support risk stratification in breast cancer survivors; leaves open prospective validation before clinical use.
Kim et al. (2021) conducted a cohort in Breast cancer (n=1,256). CHEMO-RADIAT score was evaluated on Major adverse cardiovascular events (cardiovascular mortality, myocardial infarction, congestive heart failure, and transient ischemic attack/stroke) (C-index 0.876 at 3 years and 0.842 at 7 years). The CHEMO-RADIAT score predicted major adverse cardiovascular events in breast cancer survivors with time-dependent C-indices of 0.876 at 3 years and 0.842 at 7 years in the validation cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: